REG - Allergy Therapeutics - PDMR Dealing and Total Voting Rights

Allergy TherapeuticsAnnouncement

22/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250122:nRSV1856Ua&default-theme=true

RNS Number : 1856U  Allergy Therapeutics PLC  22 January 2025

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Issue of 13 Ordinary Shares

Purchase and Cancellation of Deferred Shares

Total Voting Rights

PDMR Dealing

 

 

22 January 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, announces
that 13 ordinary shares of 0.1 pence each (the "Ordinary Shares", such
Ordinary Shares being the "New Shares") were issued at an aggregate
consideration of £1.001 for the purpose of financing the purchase of
9,848,333 deferred shares of 0.1 pence each (the "Deferred Shares")
yesterday.  Each of Dr. Shaun Furlong, Chief Financial Officer of the
Company, and Karley Cheesman, company secretary of the Company, has subscribed
for 7 New Shares and 6 New Shares, respectively. Subsequent to the issue of
the New Shares, Dr. Shaun Furlong will hold 1,507 Ordinary Shares.  In
addition, the Deferred Shares have been purchased by the Company and
subsequently cancelled yesterday.

 

The Company is pleased to confirm that, in accordance with the terms set out
in its articles of association and pursuant to the terms of a repurchase
contract approved by the shareholders at the Annual General Meeting held on 16
December 2024, all outstanding Deferred Shares have been purchased by the
Company and subsequently cancelled. As such, there are no longer any Deferred
Shares in issue. The purchase and cancellation of the Deferred Shares have no
impact on the Ordinary Shares in issue.

 

Details of the purchase of the Deferred Shares can be found in the notice of
the Annual General Meeting available on the Company's website:
https://www.allergytherapeutics.com/investors/shareholder-services/agm-information.

 

Total Voting Rights

 

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules ("DTR"), as at the date of this announcement,
the Company has 4,766,439,951 Ordinary Shares in issue. There are no shares
held in treasury. The total number of voting rights in the Company is
therefore 4,766,439,951.

 

The above figure of 4,766,439,951 may be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change in their interest in,
the share capital of the Company under DTR.

 

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

 

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Company sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com/)
.

 

 Notification and public disclosure of transactions by Director/persons
discharging managerial responsibilities ("PDMR") and persons closely
associated with them ("PCA")

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Dr. Shaun Furlong
 2   Reason for the notification
 a)  Position/status                                              Director of Allergy Therapeutics Plc.
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, UK emission allowance market participant, auction
     platform or auctioneer
 a)  Name                                                         Allergy Therapeutics plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares

 b)  Nature of the transaction                                    Issue of Ordinary Shares

 c)  Price(s) and volume(s)                                       Price                       Number of shares
     £0.539                                                                                   7

 d)  Aggregated information

     ·       - Aggregated volume                                  N/A - Single transaction

     ·       - Price
 e)  Date of the transaction                                      21 January 2025
 f)  Place of the transaction                                     London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFZGZMNMMGKZM